Guselkumab-induced vitiligo in a patient with psoriatic arthritis

Martora, Fabrizio; Annunziata, Maria Carmela; Guerriero, Luigi; Battista, Teresa; Potestio, Luca; Megna, Matteo

doi:10.1016/j.jdcr.2023.08.043

JAAD Case Reports

2023

DOI: 10.1016/j.jdcr.2023.08.043

|View full text |Cite

Guselkumab-induced vitiligo in a patient with psoriatic arthritis

Fabrizio Martora,

Maria Carmela Annunziata,

Luigi Guerriero

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo

Russell,

Daniel

2024

Aust J Dermatology

View full text Add to dashboard Cite

Vitiligo is a chronic depigmenting disorder that significantly impacts the quality of life of patients. Though there have been significant advancements in targeted therapies in skin diseases such as psoriasis or eczema, the progress in the treatment of vitiligo has been slow, with minimal studies assessing the effect of biologics, though there has been recent evidence of the effectiveness of JAK inhibition. This paper reviews the published case reports and studies for the use of systemic targeted therapies including biologics and JAK inhibitors in vitiligo.

show abstract

A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo

Russell,

Daniel

2024

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

Guselkumab - In Psoriasis and Beyond

Bubna,

Viplav

2024

Dermatology Practical &Amp; Conceptual

View full text Add to dashboard Cite

Introduction: Guselkumab is an interleukin 23p19 inhibitor, and the first in this group, to be approved by the US Food and Drug Administration (FDA) for the management of moderate to severe psoriasis. Apart from its utility in psoriasis, there are a number of other dermatologic conditions where guselkumab has demonstrated value. Objectives: The aim of this narrative review is to describe the utility of guselkumab in psoriasis as well as its implication in off-label dermatologic disorders. Methods: Pubmed, Google Scholar, Scopus and ResearchGate were searched for scholarly articles related to guselkumab and its utility in dermatology using the search terms “Guselkumab” AND “Psoriasis” AND “other dermatological disorders”. Results: Guselkumab is a valuable biologic agent for the management of psoriasis and psoriatic arthropathy. It has also been used successfully for other dermatologic disorders like hidradenitis suppurativa, lichen planus, pityriasis rubra pilaris and pyoderma gangrenosum. Recently, its utility in Stewart-Treves angiosarcoma (STA) has been exemplified. Conclusion: Guselkumab’s usage is not limited to psoriasis. Its benefit extends to many more dermatologic conditions. Its utility in STA could open an avenue for its application in the field of oncology. Furthermore, it has an acceptable safety profile.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Guselkumab-induced vitiligo in a patient with psoriatic arthritis

Cited by 2 publications

References 10 publications

A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo

A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo

Guselkumab - In Psoriasis and Beyond

Contact Info

Product

Resources

About